Ophthalmic Uses of Prednisone for Inflammatory Conditions

Clinical Application by Uveitis Type

For immune checkpoint inhibitor-related ocular toxicity, the American Academy of Ophthalmology recommends holding immunotherapy and coordinating with ophthalmology for topical corticosteroids plus cycloplegic agents for Grade 2 anterior uveitis 1
For Grade 3-4 posterior/pan-uveitis, the American Academy of Ophthalmology suggests considering systemic corticosteroids in addition to intravitreal/periocular/topical treatment as recommended by uveitis specialist 1

The American Academy of Ophthalmology advises that topical prednisolone should be limited to ≤3 months of therapy due to significant risk of elevated intraocular pressure and cataract formation 3
Using ≥2 drops/day of topical prednisolone is a strong risk factor for IOP elevation, according to the American Academy of Ophthalmology 3
Using ≥4 drops/day significantly increases cataract risk compared to ≤3 drops daily, as recommended by the American Academy of Ophthalmology 3, 4

The American Academy of Ophthalmology recommends never using prednisolone eye drops in viral corneal diseases, mycobacterial eye infections, or fungal diseases of ocular structures 2
Starting steroids before ophthalmologic examination may worsen infectious conditions like herpetic keratitis or mask accurate diagnosis, according to the American Academy of Ophthalmology 2

For noninfectious uveitis requiring control beyond 3 months, the American Academy of Ophthalmology suggests initiating noncorticosteroid immunomodulatory therapy as steroid-sparing agents 5, 6
The American Academy of Ophthalmology recommends preventing both local complications and systemic toxicity while maintaining disease control with noncorticosteroid immunomodulatory therapy 5, 7

Regular monitoring for elevated IOP and cataract formation is essential, especially when treatment extends beyond a few weeks, according to the American Academy of Ophthalmology 3